ARIDIS_LOGO.png
Aridis Provides Corporate Update
December 20, 2024 08:00 ET | Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
Picture1
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
December 17, 2024 08:30 ET | Palisade Bio, Inc.
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Logo.png
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
December 13, 2024 16:05 ET | Palisade Bio, Inc.
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Logo.png
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
December 12, 2024 12:05 ET | Palisade Bio, Inc.
Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Logo.png
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
December 03, 2024 08:15 ET | Palisade Bio, Inc.
First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,”...
Logo.png
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
November 22, 2024 09:10 ET | Biofrontera Inc.
WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization...
Logo edited.jpg
Greenwich LifeSciences Provides Update on Corporate Events
November 18, 2024 06:00 ET | Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
November 14, 2024 09:00 ET | ABVC BioPharma, Inc.
ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could...
Logo.png
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
November 13, 2024 17:15 ET | Biofrontera Inc.
 ●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton.    ●Total...
Nordicus Partners Corporation Acquires Bio-Convert ApS
November 11, 2024 14:50 ET | Nordicus Partners Corporation
Beverly Hills, California., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing...